Clinical Outcomes Study of the Nexel Total Elbow
Recruiting · Not applicable · NCT02469662
Conditions: Elbow Joint Destruction, Post-traumatic Lesions, Ankylosed Joints, Advanced Rheumatoid Arthritis, Joint Instability or Loss of Motion, Acute Comminuted Articular Fracture of Elbow Joint Surfaces, Bone Loss Contributing to Elbow Instability, Bilateral Ankylosis From Causes Other Than Active Sepsis, Post-traumatic Arthritis, Degenerative Arthritis
At a glance
- Research payments reported, 2025
- $10,982
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 134
About the trial
- Sponsor
- Zimmer Biomet
- Tested
- Nexel Total Elbow (device)
- Dates
- Started 2015-06; completion 2036-12
- Results posted
- Not yet
The objectives of the study are to confirm safety and performance of the Zimmer Nexel Total Elbow when used in primary or revision total elbow replacement.
From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Zimmer Biomet Holdings, Inc. reported $10,982 in research payments for this study in 2025 (5 payments).
Products named: Nexel
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- David J. Schneider, M.D. Sports Medicine · Golden, CO
- Nady Hamid, MD Orthopedic Surgery · Charlotte, NC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Advarra $6,920
- Wcg Irb $4,062
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.